This collection of content will continually bring you the latest news, research and FDA approvals relating to leukemia and lymphoma.
Research Shows Exposure to Glyphosate Increases Risk of Non-Hodgkin Lymphoma
Exposure to glyphosate—the world's most widely used, broad-spectrum herbicide and the primary ingredient in the weed killer Roundup—increases the risk of some cancers by more than 40 percent, according to new research from the University of Washington.
Polatuzumab Vedotin Shows Promise Among Previously Treated DLBCL Patients
Results of the GO29365 study showed that polatuzumab vedotin in combination with bendamustine plus rituximab (BR) improved median overall survival compared to BR alone (12.4 vs. 4.7 months, HR=0.42; 95% CI 0.24-0.75), in people with R/R diffuse large B-cell lymphoma (DLBCL) not eligible for a hematopoietic stem cell transplant.
MD Anderson’s Tapan Kadia, MD, highlights a few clinical trials that have the potential to change the standards of care.
Blog: The Evolving Treatment of Chronic Lymphocytic Leukemia
Over the past 5 years, the field of chronic lymphocytic leukemia (CLL) has seen the emergence of multiple new classes of therapies, including Bruton’s tyrosine kinase (BTK) inhibitors, phosphatidylinositol-3-kinase (PI3K) inhibitors, and BCL-2 inhibitors.
Tapan Kadia, MD, associate professor, Department of Leukemia, MD Anderson Cancer Center, is hopeful that the next big milestone “will be the cure of one of these diseases.”
New Therapeutic Target for GVHD Could Make Bone Marrow Transplant Safer
Bone marrow transplant (BMT) offers patients with lymphoma and leukemia a potentially curative treatment. This procedure, however, is not without risk. Graft-versus-host disease (GVHD) can develop and is associated with serious complications in transplant recipients, significantly reducing their quality of life.